EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long-Term Efficacy and Safety of Tailored Immunosuppressive Therapy in Immune-Mediated Biopsy-Proven Myocarditis: A Propensity-Weighted Study

Alida Linda Patrizia Caforio, Andrea Silvio Giordani iD, Anna Baritussio, Davide Marcolongo, Cristina Vicenzetto, Giuseppe Tarantini, Massimo Napodano, Giuseppe Toscano, Dario Gregori, Gloria Brigiari, Patrizia Bartolotta, Elisa Carturan und 5 weitere

European Journal of Heart Failure · 2024

DOI: 10.1002/ejhf.3220 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Heart Failure, 2024. Verfasst von Alida Linda Patrizia Caforio und 16 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy. Hauptthemen laut MEDLINE: Myocarditis, Immunosuppressive Agents, Propensity Score. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Standardized immunosuppressive therapy (IS) had been previously investigated in biopsy-proven (BP) lymphocytic myocarditis with heart failure (HF). This study evaluated efficacy and safety of tailored IS in BP immune-mediated myocarditis, irrespective of histology and clinical presentation. Methods and results Consecutive BP myocarditis patients treated with long-term tailored IS on top of optimal medical therapy (OMT), were compared with OMT non-IS controls using propensity-score weighting. The primary outcome was a composite of death or heart transplant, the secondary outcome was a composite of biventricular function, New York Heart Association (NYHA) class variation, and relapse. IS was managed by a multidisciplinary Cardioimmunology Team, involved a safety checklist and active patients' education. Ninety-one IS patients were compared with 267 non-IS patients. IS patients more frequently had systemic immune-mediated diseases (35% vs. 9.7%), lower baseline echocardiographic left ventricular ejection fraction (35% vs. 43%), lower right ventricular fractional area change (34% vs. 41%) and higher frequency of active lymphocytic, eosinophilic and giant cell myocarditis (71% vs. 58%, 12% vs. 1.1%, and 6.6% vs. 1.5%, respectively). At 5-year follow up, no difference was observed in the primary outcome (survival rate 93% in IS vs. 87% in non-IS), but IS patients had a higher relapse rate. Thus, IS patients, with a lower biventricular function and a higher risk profile at baseline, presented similar biventricular function and NYHA class to non-IS patients at follow-up. Minor adverse drug reactions occurred in 13% of patients, all resolved with therapy switch.

Conclusions

Prolonged tailored IS is effective and safe in BP immune-mediated myocarditis irrespective of histology and clinical presentation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MyocarditisImmunosuppressive AgentsPropensity ScoreHumansMaleFemaleMiddle AgedBiopsyAdultTreatment OutcomeRetrospective StudiesMyocardiumFollow-Up StudiesEchocardiographyHeart FailureStroke Volume

Stichwörter der Autor:innen

Endomyocardial biopsyImmunosuppressive therapyMyocarditisSystemic immune‐mediated disease

Substanzen

Immunosuppressive Agents

Autor:innen und Institutionen

  • Cardiology, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy.
  • Cardiac Surgery, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy.
  • Statistics, Department of Statistical Sciences, University of Padua, Padua, Italy.
  • Cardiovascular Pathology, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy.

ORCID-Profile: Andrea Silvio Giordani

Zitieren

APA

Caforio, A. L. P., Giordani, A. S., Baritussio, A., Marcolongo, D., Vicenzetto, C., Tarantini, G., Napodano, M., Toscano, G., Gregori, D., Brigiari, G., Bartolotta, P., Carturan, E., De Gaspari, M., Rizzo, S., Basso, C., Iliceto, S., & Marcolongo, R. (2024). Long-Term Efficacy and Safety of Tailored Immunosuppressive Therapy in Immune-Mediated Biopsy-Proven Myocarditis: A Propensity-Weighted Study. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.3220

Vancouver

Caforio ALP, Giordani AS, Baritussio A, Marcolongo D, Vicenzetto C, Tarantini G, et al. Long-Term Efficacy and Safety of Tailored Immunosuppressive Therapy in Immune-Mediated Biopsy-Proven Myocarditis: A Propensity-Weighted Study. European Journal of Heart Failure. 2024. doi:10.1002/ejhf.3220

BibTeX
@article{Caforio2024,
  author = {Caforio, Alida Linda Patrizia and Giordani, Andrea Silvio and Baritussio, Anna and Marcolongo, Davide and Vicenzetto, Cristina and Tarantini, Giuseppe and Napodano, Massimo and Toscano, Giuseppe and Gregori, Dario and Brigiari, Gloria and Bartolotta, Patrizia and Carturan, Elisa and De Gaspari, Monica and Rizzo, Stefania and Basso, Cristina and Iliceto, Sabino and Marcolongo, Renzo},
  title = {Long-Term Efficacy and Safety of Tailored Immunosuppressive Therapy in Immune-Mediated Biopsy-Proven Myocarditis: A Propensity-Weighted Study},
  journal = {European Journal of Heart Failure},
  year = {2024},
  doi = {10.1002/ejhf.3220}
}
Kostenlos starten →